Abstract:Despite the success of docetaxel in combination with trastuzumab in HER2+ breast cancer, docetaxel still has serious limitations, including poor water solubility and the canonical systemic toxicity of taxanes. These side effects of taxanes need to be overcome to improve patient management. In this context, we have developed a nanoparticle drug delivery system. We have developed an immunoliposome loaded with docetaxel and grafted with trastuzumab using a microfluidic method by mixing an aqueous phase (KH2PO4 buffer) and an organic phase composed of phosphatidylcholine, cholesterol and PEGmal in a molar ratio of 50:31:1, to which docetaxel is added at a rate of 1.8% of the total lipid. We perform a thiolation reaction to graft the trastuzumab onto the polyethylene glycol chain. Resulting immunoliposomes were characterized by a mean diameter of 140 nm, a docetaxel encapsulation rate of 73% and a trastuzumab uptake rate of 400 units of trastuzumab by nanoparticle. C57BL/6 mice were administered with docetaxel 1.9 mg/kg and trastuzumab 160 ng/kg or a mixture of free drugs or as liposomes at the same dose by intraperitoneal injection. Blood was collected 1h, 2h, 3h, 6h, 8h and 24h after injection and plasma was analyzed by HPLC-UV with Paclitaxel as internal standard. For each treatment group, pharmacokinetic parameters and exposure metrics were calculated using PKanalix®: half-life T1/2, elimination rate constant Kel and area under the curve AUC at the end points (AUCtlast) and infinity (AUCinfinity). Statistical tests were performed with Sigmastats®. The results showed a marked change in pharmacokinetics with increased plasma exposure with liposomal docetaxel. Preliminary results show a longer half-life for liposomal docetaxel (40.76 h VS. 4.33 h, i.e., a 9.4-fold increase). The concentration of docetaxel appeared to decrease more rapidly between T1h and T6h with free docetaxel (Kel 0.16h-1) than with liposomal docetaxel (Kel 0.017h-1). The concentration of docetaxel reached a plateau over time, up to 24 hours (52.72± 9.45 ng/ml) in mice treated with immunoliposomes whereas Docetaxel was undetectable at T24h when treated with free drugs. There was a statistical difference in PK at T6h between liposomal docetaxel and free docetaxel, 69.86 ± 15.25 ng/ml and 53.67 ± 4.92 ng/ml, respectively (p < 0.001, non-paired t-test). Liposomal docetaxel showed higher AUC0-t (x3.75) and AUC0-∞ values (x5.9) compared to non-liposomal docetaxel. In conclusion, these preliminary results suggest that we have developed a promising immunoliposome for the systemic delivery of docetaxel in HER2+ breast cancer with sustained exposure. Citation Format: Mathilde Dacos, Erwan Diroff, Sarah Giacometti, Joseph Ciccolini, Raphaelle Fanciullino. Animal pharmacokinetics of an anti-Her2+ immunoliposome of docetaxel [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 7173.

An Intravenous Lipid Emulsion of Docetaxel based on Phospholipid Complex Strategy: Evaluation In vitro and In vivo

Enhanced Oral Bioavailability of Docetaxel by Lecithin Nanoparticles: Preparation, in Vitro, and in Vivo Evaluation

Preparation and studies of docetaxel proliposome

A lyophilized sterically stabilized liposome-containing docetaxel: in vitro and in vivo evaluation

Development of Polysorbate 80/phospholipid Mixed Micellar Formation for Docetaxel and Assessment of Its in Vivo Distribution in Animal Models

Enhanced antitumor efficacy and decreased toxicity by self-associated docetaxel in phospholipid-based micelles.

A novel monomethoxy polyethylene glycol-polylactic acid polymeric micelles with higher loading capacity for docetaxel and well-reconstitution characteristics and its anti-metastasis study

A novel polyethylene glycol mediated lipid nanoemulsion as drug delivery carrier for paclitaxel

An Optimized Two-Vial Formulation Lipid Nanoemulsion of Paclitaxel for Targeted Delivery to Tumor.

Preparation and Evaluation of Lipid Emulsified Docetaxel-Loaded Nanoparticles.

In Vitro and in Vivo Evaluation of Folate Receptor-Targeting Amphiphilic Copolymer-Modified Liposomes Loaded with Docetaxel.

Docetaxel Prodrug Liposomes for Tumor Therapy: Characterization, in Vitro and in Vivo Evaluation

Abstract 7173: Animal pharmacokinetics of an anti-Her2+ immunoliposome of docetaxel

The Fabrication of Docetaxel-Containing Emulsion for Drug Release Kinetics and Lipid Peroxidation

Arginine-stabilized Mpeg-Pdlla (50/50) Polymeric Micelles of Docetaxel by Electrostatic Mechanism for Tumor-Targeted Delivery.

N-octyl-O-sulfate Chitosan-Modified Liposomes for Delivery of Docetaxel: Preparation, Characterization, and Pharmacokinetics

Tumor-targeting intravenous lipid emulsion of paclitaxel: Characteristics, stability, toxicity, and toxicokinetics

Pluronic P105/F127 mixed micelles for the delivery of docetaxel against Taxol-resistant non-small cell lung cancer: optimization and in vitro, in vivo evaluation.

Preparation, Characterization, and in Vitro Evaluation of Docetaxel-Loaded Poly(lactic Acid)-Poly(ethylene Glycol) Nanoparticles for Parenteral Drug Delivery.

A Novel Lipid-Based Nanomicelle of Docetaxel: Evaluation of Antitumor Activity and Biodistribution

Preparation and Evaluation in Vitro and in Vivo of Docetaxel Loaded Mixed Micelles for Oral Administration.